OTLK
Outlook Therapeutics
$1.07
−$0.34 (−24.2%)Jul 27, 2026
Key metrics
The numbers that frame OTLK today
- Market cap
- $128.72M
- P/E (TTM)
- -2.1
- EV / FCF
- -3.1
- Gross margin
- -360.9%
- EV / Sales
- 444.7
- ROIC
- -2,177.2%
- Div yield
- 0%
- 52wk Low
- $0.16
- 52wk High
- $3.39
Growth
Revenue and earnings trend for OTLK
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about OTLK
Is Outlook Therapeutics a good buy?
Hold. Outlook Therapeutics has excellent momentum, but poor quality makes the setup mixed. Growth looks excellent, which supports the long-term business case. We think Outlook Therapeutics is selling at a very high price.
What is the market capitalization of OTLK?
Outlook Therapeutics's market capitalization is $128.72M.
What is the P/E ratio for OTLK stock?
Outlook Therapeutics's current P/E ratio is -2.1.
What is the 52-week high for OTLK stock?
The 52-week high for Outlook Therapeutics is $3.39. The current close of $1.07 is 68.6% below that high.
What is the 52-week low for OTLK stock?
The 52-week low for Outlook Therapeutics is $0.16. The current close of $1.07 is 561.5% above that low.
Does OTLK stock pay dividends?
Outlook Therapeutics does not currently show a dividend per share in the company data.